武田制药、诺和诺德终止 细胞疗法迎来“淘汰赛”导语:曾经备受资本追捧的细胞疗法领域,开始迎来一场不可避免的大洗牌。2025年秋,全球生物医药领域接连传来震动性消息,武田制药宣布全面停止细胞疗法相关业务,彻底告别CGT赛道。紧随其后,诺和诺德终止所有细胞疗法研发项目,近250名相关部门员工面临失业。曾经炙手可热的细胞疗法为何成了医药巨头们的“弃子”?巨头撤场的无奈早在2017年,武田就开始布局细胞...
Source Link武田制药、诺和诺德终止 细胞疗法迎来“淘汰赛”导语:曾经备受资本追捧的细胞疗法领域,开始迎来一场不可避免的大洗牌。2025年秋,全球生物医药领域接连传来震动性消息,武田制药宣布全面停止细胞疗法相关业务,彻底告别CGT赛道。紧随其后,诺和诺德终止所有细胞疗法研发项目,近250名相关部门员工面临失业。曾经炙手可热的细胞疗法为何成了医药巨头们的“弃子”?巨头撤场的无奈早在2017年,武田就开始布局细胞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.